Day One Biopharmaceuticals is Servier’s greatest acquisition but, topping the $2.4 billion it paid to purchase Shire’s most cancers enterprise in 2018. Day One markets Ojemda, permitted for treating pediatric low-grade glioma, the commonest sort of mind most cancers in youngsters.
The publish Servier Boosts Presence in Uncommon Cancers With $2.5B Acquisition of Day One Biopharma appeared first on MedCity Information.
